The Technical Analyst
Iveric Bio Inc [ISEE]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Iveric Bio Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.38% $39.95
America/New_York / 10 jul 2023 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 5 512.18 mill |
| EPS: | -1.780 |
| P/E: | -22.44 |
| Earnings Date: | Jul 23, 2023 |
| SharesOutstanding: | 137.98 mill |
| Avg Daily Volume: | 4.95 mill |
| RATING 2023-07-10 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/21 | 1/22 | 2/22 | 3/22 | 4/22 | 1/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -22.44 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -3.82x |
| Company: PE -22.44 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 39.43 - 40.47 ( +/- 1.29%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-07-11 | Blumenkranz Mark S. | Sell | 32 088 | Common Stock |
| 2023-07-11 | Blumenkranz Mark S. | Sell | 7 500 | Restricted Stock Units |
| 2023-07-11 | Blumenkranz Mark S. | Sell | 31 000 | Stock Option (Right to Buy) |
| 2023-07-11 | Blumenkranz Mark S. | Sell | 15 500 | Stock Option (Right to Buy) |
| 2023-07-11 | Blumenkranz Mark S. | Sell | 23 186 | Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| -97.75 |
| Last 100 transactions |
| Buy: 73 584 | Sell: 6 010 653 |
Forecast:
01:40 - $43.01
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $39.95 (0.38% ) |
| Volume | 10.80 mill |
| Avg. Vol. | 4.95 mill |
| % of Avg. Vol | 218.40 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ISEE
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ISEE
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). It also develops STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of leber congenital amaurosis type 10 (LCA10) and autosomal recessive stargardt disease (STGD1); IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases; IC-100 for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa; and IC-200 for the treatment of IRDs associated with mutations in the BEST1 gene. In addition, the company develops OPH2001 that has completed Phase 1/2a clinical trial of various doses of Zimura monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of Zimura administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. Its discovery and research programs include miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and miniUSH2A Program for usher syndrome type 2A-Related IRDs. The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. The company was incorporated in 2007 and is based in Parsippany, New Jersey.
Latest Press Releases
2023-09-20 09:00:00 - Press Release
Two-time Emmy® Award-winning Actor, Eric Stonestreet, Partners With Iveric Bio To Raise Awareness Of Geographic Atrophy (ga)
Ga is a form of age-related macular degeneration (amd) that causes irreversible vision loss, affecting approximately 1.5 million people in the united states 1,2 eric and his mother, jamey, are sharing their family's story of ga and amd to raise awareness of the disease northbrook, ill. , sept. 20, 2023 /prnewswire/ -- iveric bio, an astellas company (tse: 4503, president and ceo: naoki okamura, "astellas"), today announced a partnership with two-time emmy® award-winning actor, eric stonestreet, to raise awareness about geographic atrophy (ga), a form of age-related macular degeneration (amd) that causes irreversible vision loss.1 eric and his mother, jamey, are sharing how ga and amd has affected their family to inspire others to learn about the disease and be proactive around their eye health as part of the campaign.
2023-09-18 19:00:00 - Press Release
Iveric Bio Announces Positive 24-month Topline Results From Phase 3 Study Of Izervay™ (avacincaptad Pegol Intravitreal Solution) For Geographic Atrophy
Gather2 24-month results met the primary objective of reducing the rate of ga growth in patients treated with izervay compared to sham izervay 24-month safety data were consistent with 12-month results , with no new safety signals identified tokyo, sept. 18, 2023 /prnewswire/ -- astellas pharma inc. (tse: 4503, president and ceo: naoki okamura, "astellas") today announced positive 24-month topline results from the phase 3 gather2 clinical trial evaluating the efficacy and safety of izervay™ (avacincaptad pegol intravitreal solution), a complement c5 inhibitor for the treatment of geographic atrophy (ga) secondary to age-related macular degeneration (amd).
2023-08-17 19:30:00 - Press Release
European Medicines Agency Accepts Iveric Bio's Marketing Authorization Application For Avacincaptad Pegol For Geographic Atrophy
Tokyo , aug. 18, 2023 /prnewswire/ -- astellas pharma inc. (tse: 4503, president and ceo: naoki okamura, "astellas"), today announced the european medicines agency (ema) has accepted for regulatory review the marketing authorization application (maa) for avacincaptad pegol (acp), an investigational complement c5 inhibitor for the treatment of geographic atrophy (ga) secondary to age-related macular degeneration (amd). the committee for medicinal products for human use (chmp) of the ema will start its review of the maa under the centralized licensing procedure for all 27 member states of the european union (eu).
2023-08-04 21:24:00 - Press Release
Iveric Bio Receives U.s. Fda Approval For Izervay™ (avacincaptad Pegol Intravitreal Solution), A New Treatment For Geographic Atrophy
Izervay is the only approved ga treatment with a statistically significant reduction in the rate of ga progression at the 12-month primary endpoint across two phase 3 clinical trials izervay slowed loss of photoreceptors and disease progression as early as six months ga impacts an estimated 1.5 million people in the u.s. and can cause irreversible vision loss tokyo , aug. 5, 2023 /prnewswire/ -- astellas pharma inc. (tse: 4503, president and ceo: naoki okamura, "astellas"), today announced the u.s. food and drug administration (fda) approved izervay™ (avacincaptad pegol intravitreal solution) for the treatment of geographic atrophy (ga) secondary to age-related macular degeneration (amd) on august 4, 2023...
2023-07-11 19:00:00 - Press Release
Astellas Completes Acquisition Of Iveric Bio
Tokyo and parsippany, n.j. , july 11, 2023 /prnewswire/ -- astellas pharma inc. (tse: 4503, president and ceo: naoki okamura, "astellas") today announced that it has successfully completed the acquisition of iveric bio, inc. (nasdaq: isee, ceo: glenn p. sblendorio, "iveric bio") with respect to the announcement on april 30, 2023, through its indirect wholly-owned subsidiary berry merger sub, inc. (the "acquisition"). the acquisition was completed on july 11, 2023, us eastern time, as follows, and iveric bio has become astellas' wholly-owned subsidiary.
Latest News
2023-07-28 18:02:38 - GuruFocus
Deep Track Capital, LP Acquires New Stake in Terns Pharmaceuticals Inc
Deep Track Capital, LP (Trades, Portfolio), a prominent investment firm, recently made a significant move in the stock market by acquiring a new stake in Terns Pharmaceuticals Inc. This article will delve into the details of this transaction, provide an overview of both the guru and the traded company, and analyze the potential implications of this move for value investors.
2023-05-01 20:58:33 - Bloomberg Markets and Finance
Astellas Pharma CEO Says Confident of Iveric Bio Drug Approval
Naoki Okamura, chief executive officer of Japanese drugmaker Astellas Pharma Inc., discusses his company's decision to acquire Iveric Bio Inc., a developer of drugs to treat age-related blindness, for about $5.9 billion. He also talks about Astellas Pharma's growth strategy with Shery Ahn and Haidi Stroud-Watts on "Bloomberg Daybreak: Asia.
2023-05-01 15:13:52 - Proactive Investors
Iveric Bio stock surges on Astellas Pharma takeover deal
Iveric Bio Inc shares climbed 16% to $38.01 on Monday after the US drugmaker agreed to be acquired by Japan's Astellas Pharma for $40 per share in cash or total consideration of about $5.9 billion. Iveric's primary asset is avacincaptad pegol (ACP) which is currently in trials for treating geographic atrophy, the advanced stage of macular degeneration, a common cause of vision loss in the elderly.
2023-05-01 10:01:40 - Investors Business Daily
Biotech Buying Bonanza: Iveric Bio Snags $5.9 Billion Deal From Astellas Pharma
Astellas Pharma snapped up Iveric Bio for $5.9 billion in cash, the companies said Monday in an announcement that sent ISEE stock flying. The post Biotech Buying Bonanza: Iveric Bio Snags $5.9 Billion Deal From Astellas Pharma appeared first on Investor's Business Daily.
2023-05-01 06:00:00 - Barrons
Iveric Bio Stock Surges. It's Being Bought by Astellas for $5.9 Billion.
Japan's Astellas agrees to pay $40 a share for Iveric, citing the potential of the biopharmaceutical company's ophthalmology programs.
2023-05-01 01:34:00 - Market Watch
Japan's Astellas Pharma to buy Iveric Bio in deal worth $5.9 billion
Astellas Pharma Inc. said Monday that it agreed to acquire Iveric bio Inc. for about $5.9 billion to strengthen its capabilities in the ophthalmology field.
2023-03-06 22:55:40 - 24/7 Wall Street
These Are the Top 10 Holdings of David Kim
David Kim is the founder and Chief Investment Officer of Ghost Tree Capital. Before founding Ghost Tree Capital in 2013, Kim worked as the portfolio manager at Diamondback Capital (Nov 2006 – Dec 2012).
2022-11-18 14:34:03 - InvestorPlace
Why Is Iveric Bio (ISEE) Stock Up 25% Today?
Against a relatively flat backdrop for the major equity indices, biotechnology firm Iveric Bio (NASDAQ: ISEE ) provided a decisively positive framework, with shares gaining 25% on Friday afternoon. Yesterday, the company disclosed receiving a breakthrough therapy designation for its flagship therapeutic candidate from the Food and Drug Administration (FDA).
2022-11-05 22:42:04 - Seeking Alpha
IVERIC bio, Inc. (ISEE) Q3 2022 Earnings Call Transcript
IVERIC bio, Inc. (NASDAQ:ISEE ) Q3 2022 Earnings Conference Call November 3, 2022 8:00 AM ET Company Participants Kathy Galante - SVP, IR & Corporate Communications Glenn Sblendorio - CEO & Director Pravin Dugel - President David Carroll - SVP, CFO & Treasurer Conference Call Participants Kenneth Cacciatore - Cowen and Company Gregory Harrison - Bank of America Merrill Lynch Colleen Kusy - Robert W. Baird & Co. Eliana Merle - UBS Annabel Samimy - Stifel Kambiz Yazdi - Jefferies Michael Ulz - Morgan Stanley David Nierengarten - Wedbush Securities Eddie Hickman - Guggenheim Securities Operator Good day, and welcome to the Iberia Third Quarter 2022 Earnings Conference Call.
2022-11-04 16:30:00 - Business Wire
Iveric Bio to Present at Upcoming Investor Conferences
